More Oncology Drugs Available In U.S. But Australians Pay 30% Less - Tufts Study
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development